Otsuka (OTCMKTS:OTSKY) Updates FY 2026 Earnings Guidance

Otsuka (OTCMKTS:OTSKY) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 2.119-2.119 for the period, compared to the consensus EPS estimate of 1.980. The company issued revenue guidance of $17.1 billion-$17.1 billion, compared to the consensus revenue estimate of $16.7 billion.

Otsuka Trading Down 4.0%

Shares of Otsuka stock traded down $1.42 during trading on Friday, reaching $34.41. 50,665 shares of the company were exchanged, compared to its average volume of 39,974. The business has a 50-day moving average price of $34.19 and a 200-day moving average price of $33.51. The firm has a market capitalization of $36.96 billion and a price-to-earnings ratio of 14.52. The company has a quick ratio of 1.67, a current ratio of 2.17 and a debt-to-equity ratio of 0.05. Otsuka has a twelve month low of $23.67 and a twelve month high of $37.52.

Otsuka (OTCMKTS:OTSKY) last released its earnings results on Friday, July 31st. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.51 by $0.19. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.Otsuka has set its FY 2026 guidance at 2.119-2.119 EPS. Sell-side analysts anticipate that Otsuka will post 1.96 EPS for the current fiscal year.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.